Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker GSK · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Mass Balance and Absolute Bioavailability of [14C]-VH4011499 NCT07934719 · HIV Infections VH4011499, [14C]-VH4011499 (IV) | GSK ViiV Healthcare | Phase 1 | Not yet recruiting | 18 | Feb 18, 2027 | Registry ↗ |
| Nov 13, 2026 | A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Heal… NCT07393659 · HIV Infections Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC) | GSK ViiV Healthcare | Phase 3 | Recruiting | 197 | Sep 14, 2032 | Registry ↗ |
| Nov 13, 2026 | A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Partici… NCT06613698 · Liver Diseases, Alcoholic GSK4532990, Placebo | GSK GlaxoSmithKline | Phase 2 | Recruiting | 350 | Nov 26, 2027 | Registry ↗ |
| Nov 13, 2026 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Dara… NCT04246047 · Multiple Myeloma Belantamab mafodotin, Daratumumab | GSK GlaxoSmithKline | Phase 3 | Active, not recruiting | 494 | Oct 2, 2023 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult… NCT07791043 · Liver Diseases, Alcoholic Efimosfermin alfa, Placebo | GSK GlaxoSmithKline | Phase 2 | Recruiting | 274 | Aug 11, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants… NCT07782996 · Asthma GSK5784283, Placebo | GSK GlaxoSmithKline | Phase 3 | Recruiting | 370 | May 4, 2029 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo… NCT07780669 · Pulmonary Disease, Chronic Obstructive GSK5784283, Placebo | GSK GlaxoSmithKline | Phase 3 | Recruiting | 624 | Jul 20, 2029 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo… NCT07780656 · Pulmonary Disease, Chronic Obstructive GSK5784283, Placebo | GSK GlaxoSmithKline | Phase 3 | Recruiting | 624 | Jul 20, 2029 | Registry ↗ |
| Nov 12, 2026 | A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE… NCT07202546 · HIV Infections VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (T… | GSK ViiV Healthcare | Phase 2 | Recruiting | 186 | Oct 28, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Hea… NCT06576271 · Systemic Lupus Erythematosus GSK4527363, Placebo matching GSK4527363 | GSK GlaxoSmithKline | Phase 1 | Active, not recruiting was recruiting | 143 | Feb 1, 2028 | Registry ↗ |
| Nov 12, 2026 | Phase 2b Study of GSK4532990 in Adults With NASH NCT05583344 · Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver… GSK4532990, Placebo | GSK GlaxoSmithKline | Phase 2 | Completed was active, not recruiting | 284 | Jan 31, 2026 | Registry ↗ |
| Nov 10, 2026 | A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting… NCT07650916 · HIV CAB ULA, RPV ULA | GSK ViiV Healthcare | Phase 3 | Recruiting | 564 | Aug 13, 2029 | Registry ↗ |
| Nov 10, 2026 | A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Fa… NCT07545681 · Malaria, Falciparum GSK3772701 600 mg, GSK3772701 900 mg | GSK GlaxoSmithKline | Phase 2 | Recruiting was not yet recruiting | 70 | Oct 8, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] NCT07099898 · Neoplasms, Lung Risvutatug rezetecan (Ris-Rez), Topotecan | GSK GlaxoSmithKline | Phase 3 | Recruiting | 420 | Nov 5, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA… NCT06694805 · HIV Infections CAB LA + RPV LA, Oral ART | GSK ViiV Healthcare | Phase 3 | Active, not recruiting | 326 | Aug 19, 2026 | Registry ↗ |
| Nov 10, 2026 | REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal r… NCT06041386 · Asthma Mepolizumab, Spirometry | GSK GlaxoSmithKline | Phase 4 | Active, not recruiting | 177 | Feb 12, 2026 | Registry ↗ |
| Nov 10, 2026 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma NCT03763370 · Multiple Myeloma Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd), Belan… | GSK GlaxoSmithKline | — | Approved for marketing was available | — | — | Registry ↗ |
| Nov 10, 2026 | Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Pl… NCT02951052 · Infection, Human Immunodeficiency Virus, HIV Infections Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet | GSK ViiV Healthcare | Phase 3 | Active, not recruiting | 618 | May 29, 2018 | Registry ↗ |
| Nov 9, 2026 | First-Time-in-Human Study of GSK5471713 in Adults With mCRPC NCT07332455 · Neoplasms, Prostate GSK5471713 | GSK GlaxoSmithKline | Phase 1/2 | Recruiting | 54 | Mar 24, 2028 | Registry ↗ |
| Nov 9, 2026 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-actin… NCT06786520 · HIV Infections CAB LA, CAB ULA | GSK ViiV Healthcare | Phase 1 | Active, not recruiting | 69 | Mar 8, 2027 | Registry ↗ |
| Nov 9, 2026 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Adv… NCT05565378 · Lung Cancer, Non-Small Cell Pembrolizumab, Dostarlimab | GSK GlaxoSmithKline | Phase 2 | Active, not recruiting | 351 | Oct 26, 2026 | Registry ↗ |
| Nov 9, 2026 | A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Ag… NCT05298254 · Herpes Simplex 40 µg gE-gI, 80 µg gE-gI | GSK GlaxoSmithKline | Phase 1/2 | Completed | 504 | Jun 12, 2025 | Registry ↗ |
| Nov 9, 2026 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma NCT04091126 · Multiple Myeloma Belantamab mafodotin, Bortezomib | GSK GlaxoSmithKline | Phase 1 | Active, not recruiting | 118 | Jun 2, 2025 | Registry ↗ |
| Nov 6, 2026 | A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Particip… NCT06995430 · Meningitis rMenB+OMV NZ vaccine | GSK GlaxoSmithKline | Phase 3 | Completed | 312 | Dec 15, 2025 | Registry ↗ |
| Nov 6, 2026 | A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Asso… NCT06551181 · Respiratory Syncytial Virus Infections RSVPreF3 OA investigational vaccine, Placebo (Saline soluti… | GSK GlaxoSmithKline | Phase 3 | Completed | 2,620 | Apr 24, 2025 | Registry ↗ |
| Nov 6, 2026 | A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Pa… NCT06537414 · Chronic Hepatitis B Virus Infection, Hepatitis B Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisir… | GSK GlaxoSmithKline | Phase 2 | Active, not recruiting | 283 | May 31, 2027 | Registry ↗ |
| Nov 6, 2026 | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatiti… NCT06497504 · Hepatitis B Bepirovirsen, Placebo | GSK GlaxoSmithKline | Phase 2 | Active, not recruiting | 153 | Apr 22, 2027 | Registry ↗ |
| Nov 6, 2026 | A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI)… NCT06433921 · Asthma, Mild Asthma Salbutamol HFA-152a, Salbutamol HFA-134a | GSK GlaxoSmithKline | Phase 1 | Recruiting | 84 | Apr 16, 2027 | Registry ↗ |
| Nov 6, 2026 | A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary… NCT06154837 · Pulmonary Disease, Chronic Obstructive GSK3862995B, Placebo | GSK GlaxoSmithKline | Phase 1 | Active, not recruiting | 127 | Dec 16, 2026 | Registry ↗ |
| Nov 6, 2026 | Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangi… NCT05448170 · Pruritus Linerixibat | GSK GlaxoSmithKline | — | Available | — | — | Registry ↗ |
| Nov 5, 2026 | A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chroni… NCT07782970 · Nasal Polyps GSK5784283, Placebo | GSK GlaxoSmithKline | Phase 3 | Recruiting | 218 | Mar 6, 2029 | Registry ↗ |
| Nov 5, 2026 | A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate… NCT07747480 · Colitis, Ulcerative Aletekitug | GSK GlaxoSmithKline | Phase 1 | Recruiting was not yet recruiting | 16 | Mar 5, 2028 | Registry ↗ |
| Nov 5, 2026 | A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of… NCT07712393 · Asthma GSK5784283 | GSK GlaxoSmithKline | Phase 1 | Active, not recruiting was recruiting | 24 | Apr 13, 2027 | Registry ↗ |
| Nov 5, 2026 | A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participa… NCT07704892 · Metabolic Dysfunction-associated Steatohepatitis Efimosfermin alfa, Placebo | GSK GlaxoSmithKline | Phase 3 | Recruiting | 380 | Oct 16, 2030 | Registry ↗ |
| Nov 5, 2026 | A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Place… NCT07701993 · Metabolic Dysfunction-associated Steatohepatitis Efimosfermin alfa, Placebo | GSK GlaxoSmithKline | Phase 3 | Recruiting | 1,740 | Jun 23, 2033 | Registry ↗ |
| Nov 5, 2026 | A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (… NCT07645248 · Asthma HFA-152a, HFA-134a | GSK GlaxoSmithKline | Phase 3 | Recruiting | 110 | Dec 28, 2026 | Registry ↗ |
| Nov 5, 2026 | A Study of Efimosfermin Alfa in Adults With Hepatic Impairment NCT07358546 · Non-alcoholic Fatty Liver Disease Efimosfermin alfa | GSK GlaxoSmithKline | Phase 1 | Recruiting | 32 | Oct 13, 2027 | Registry ↗ |
| Nov 5, 2026 | Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children NCT07320716 · Diarrhoea AltSonflex1-2-3, Menveo | GSK GlaxoSmithKline | Phase 2 | Recruiting was not yet recruiting | 179 | Oct 16, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to C… NCT07220109 · Respiratory Syncytial Virus Infections RSVPreF3 OA vaccine, Placebo | GSK GlaxoSmithKline | Phase 3 | Active, not recruiting | 750 | Jul 20, 2026 | Registry ↗ |
| Nov 5, 2026 | A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to M… NCT06920043 · Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoh… Efimosfermin, Placebo | GSK GlaxoSmithKline | Phase 2 | Recruiting | 42 | Jul 3, 2028 | Registry ↗ |
| Nov 5, 2026 | First Time in Human Study of Long Acting VH4524184 Formulations NCT06310551 · HIV Infections Oral VH4524184, VH4524184 Formulation A SC | GSK ViiV Healthcare | Phase 1 | Recruiting | 348 | May 28, 2029 | Registry ↗ |
| Nov 5, 2026 | Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Par… NCT06134362 · HIV Infections CAB LA | GSK ViiV Healthcare | Phase 3 | Active, not recruiting | 2,998 | Mar 14, 2029 | Registry ↗ |
| Nov 5, 2026 | A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to St… NCT05996471 · HIV Infections VH3810109, Cabotegravir | GSK ViiV Healthcare | Phase 2 | Active, not recruiting | 185 | May 27, 2026 | Registry ↗ |
| Nov 5, 2026 | Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Stu… NCT04954859 · Hepatitis B Bepirovirsen, Placebo | GSK GlaxoSmithKline | Phase 2 | Active, not recruiting | 366 | Jan 24, 2029 | Registry ↗ |
| Nov 4, 2026 | A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Ad… NCT07915791 · Pulmonary Disease, Chronic Obstructive GSK3862995B, GSK5784283 | GSK GlaxoSmithKline | Phase 2 | Not yet recruiting | 279 | Mar 16, 2029 | Registry ↗ |
| Nov 4, 2026 | Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent My… NCT06517875 · Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis… Momelotinib, Luspatercept | GSK GlaxoSmithKline | Phase 2 | Recruiting | 68 | Mar 16, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-old… NCT05757102 · Asthma FF/UMEC/VI, ELLIPTA | GSK GlaxoSmithKline | Phase 3 | Active, not recruiting was recruiting | 138 | Jan 26, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus R… NCT05418868 · HIV Infections Cabotegravir 200 mg/mL, CAB >=400 mg/mL | GSK ViiV Healthcare | Phase 1 | Recruiting | 214 | Mar 31, 2028 | Registry ↗ |
| Nov 3, 2026 | Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian… NCT07694427 · Ovarian Neoplasms Mocertatug rezetecan, Bevacizumab | GSK GlaxoSmithKline | Phase 3 | Recruiting was not yet recruiting | 720 | Sep 6, 2029 | Registry ↗ |
| Nov 3, 2026 | A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp End… NCT07684599 · Neoplasms, Endometrial Mocertatug rezetecan, Dostarlimab | GSK GlaxoSmithKline | Phase 3 | Recruiting | 610 | Jul 23, 2029 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances